Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized placebo-controlled trial of macrogol 4000 for children with functional abdominal pain
NL-OMON43096Withdrawn
- Sponsor
- HagaZiekenhuis
- Start
- May 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial of macrogol 4000 in functional abdominal pain (FAP), irritable bowel syndrome (IBS) and functional dyspepsia (FD), sponsored by HagaZiekenhuis. Primary endpoint: Complete remission of pain. Planned start May 2016; status: withdrawn.
02
Drugs
macrogol 4000
03
Conditions
functional abdominal pain (FAP)irritable bowel syndrome (IBS)functional dyspepsia (FD)
Beyond the preview
Go deeper on NL-OMON43096.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON43096.